Tizanidne Hydrochloride Capsule
Product Images NDC 72162-1861

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Tizanidne Hydrochloride (NDC 72162-1861). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl721621861)

Tizanidine Hydrochloride Capsules 4 mg oral dosage form by Bryant Ranch Prepack. The label shows the 4 mg strength, containing 4.58 mg Tizanidine Hydrochloride equivalent to 4 mg Tizanidine base, with a package size of 150 capsules. Manufactured by Alkem Laboratories Ltd. Instructions for storage and dispensing are also included.*

FDA Label Image

Tiz01 (Tiz01)

Chemical structure of Tizanidine hydrochloride depicted as a two-dimensional molecular structure showing connected atoms including chlorine, nitrogen, sulfur, and hydrogen.*

FDA Label Image

Tiz02 (Tiz02)

A line graph showing plasma tizanidine concentration (ng/mL) over time (hours from dosing) for 4 mg tizanidine tablets and capsules, both with and without food. The graph compares how food intake affects the plasma concentration levels following oral dosing over a 24-hour period.*

FDA Label Image

Tiz03 (Tiz03)

A line graph showing the improvement in Ashworth score over time (hours post-dose) for three groups: 16 mg tizanidine, 8 mg tizanidine, and placebo. The y-axis represents improvement in Ashworth score, ranging from 1 to -5, and the x-axis shows time from 0 to 6 hours post-dose. The 16 mg tizanidine group shows the greatest improvement, peaking around 2 hours, followed by the 8 mg group, with placebo showing minimal change.*

FDA Label Image

Tiz04 (Tiz04)

A line chart comparing improvement in Ashworth Score at three time points: End of Titration (Week 3), End of Maintenance (Week 7), and Endpoint with last observation carried forward. The chart shows mean scores with error bars for tizanidine (mean dose 28.8 mg) and placebo groups, indicating greater improvement in the tizanidine group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.